olaparib tablets,
for oral use Initial U.S. Approval: 2014

As specified in the prescribing information, olaparib tablets is indicated for the treatment of Ovarian cancer and Breast cancer.  Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer and Breast cancer.

Facts about olaparib tablets

Approval Date: 2014
Proprietary Name: LYNPARZA (olaparib) tablets
Active Ingredient(s): olaparib
FDA-approved use: Ovarian cancer and Breast cancer.
Dosage Form: Tablets: 150 mg, 100 mg
Medicine Approved By: US FDA
Manufacturer: AstraZeneca
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “olaparib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.